Midatech Pharma PLC Midatech presenting at the Shares/AJ Bell Webinar

TIDMMTPH

Midatech Pharma PLC

24 November 2021

REACH

24 November 2021

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech presenting at the Shares and AJ Bell Webinar

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that the Company's CEO and CFO, Stephen Stamp, will be presenting at the Shares and AJ Bell investor webinar on Wednesday 1 December 2021 at approximately 19.20 GMT.

The Shares and AJ Bell evening webinars are an opportunity for senior board directors from quoted companies to make a presentation about their company and update existing and potential investors on their business plans.

Shareholders and potential investors can register to join the webinar for free at:

https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-011221

For more information, please contact:

 
 Midatech Pharma PLC 
 Stephen Stamp, CEO, CFO 
 Tel: [phone] 
 www.midatechpharma.com 
 
 IFC Advisory Limited (Financial PR and UK Investor Relations) 
 Tim Metcalfe / Graham Herring 
 Tel: [phone] 
 Email: [e-mail] 
 
             About Midatech Pharma PLC 
             Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
             MTP) is a drug delivery technology company focused on improving 
             the bio-delivery and bio-distribution of medicines. The Company 
             combines approved and development medications with its proprietary 
             and innovative drug delivery technologies to provide compelling 
             products that have the potential to powerfully impact the 
             lives of patients. 
             The Company has developed three in-house technology platforms, 
             each with its own unique mechanism to improve delivery of 
             medications to sites of disease. All of the Company's technologies 
             have successfully entered human use in the clinic, providing 
             important validation of the potential for each platform: 
              *    Q-Sphera(TM) platform: a disruptive micro-technology 
                   used for sustained release to prolong and control the 
                   release of therapeutics over an extended period of 
                   time (from weeks to months). 
 
 
              *    MidaSolve(TM) platform: an innovative nanotechnology 
                   used to dissolve insoluble drugs so that they can be 
                   administered in liquid form directly and locally into 
                   tumours. 
 
 
              *    MidaCore(TM) platform: a leading-edge nanotechnology 
                   used for targeting medications to sites of disease. 
 
 
 
             The platform nature of the technologies offers the potential 
             to develop multiple drug assets rather than being reliant 
             on a limited number of programmes. Midatech's technologies 
             are supported by 36 patent families including 120 granted 
             patents and an additional 70 patent applications. Midatech's 
             headquarters and R&D facility is in Cardiff, UK. For more 
             information please visit www.midatechpharma.com 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAPPGQGGUPGGCW

(END) Dow Jones Newswires

November 24, 2021 02:00 ET (07:00 GMT)